New York, June 2, 2026, 10:11 EDT
- Cardio Diagnostics shares were recently up 6.6% at $2.27 after closing 12.7% higher on Monday.
- The next visible test for the company is a June conference push aimed at employers, brokers and health-plan buyers.
- Its latest quarterly filing showed $2,680 in revenue and a $1.79 million net loss.
Cardio Diagnostics Holdings Inc shares rose again on Tuesday, extending the prior session’s jump, as traders focused on the micro-cap cardiovascular diagnostics firm’s push into employer health-benefit channels rather than a fresh earnings report. Micro-cap means a company with a very small stock-market value.
The stock was recently at $2.27, up 6.6%, giving the Chicago-based company a market value of about $6.45 million. Shares closed Monday at $2.13, up 12.7%, on volume of 95,943 shares.
Why it matters now is timing. Cardio Diagnostics said last week it would exhibit at four national benefits conferences in June, starting with the Greater Philadelphia Business Coalition on Health annual conference on June 4 and another Philadelphia event on June 9. The company is trying to reach employers, brokers, union trustees and plan administrators at a point when medical-cost inflation remains a boardroom issue.
The company’s pitch is that cardiovascular disease can be tackled earlier, before a costly heart event. It markets Epi+Gen CHD and PrecisionCHD, blood tests that combine epigenetics, genetics and artificial intelligence. Epigenetics refers to changes that affect how genes work without changing the DNA sequence itself; artificial intelligence is software used to find patterns in data.
Cardio also pairs the tests with HeartRisk, a population-risk platform meant to help plan sponsors assess cardiovascular risk across a workforce or membership. Chief Executive Meesha Dogan said benefits strategies should “bring spend down and keep individuals healthier,” adding that cardiovascular disease is “largely preventable when risk is identified early.” Business Wire
The market move comes from a low base. In its first-quarter filing, Cardio reported revenue of $2,680 and a net loss of $1.79 million for the three months ended March 31. Cash stood at $7.08 million, and operations used $1.56 million in the quarter.
Funding remains central to the story. Cardio said it had sold 2.25 million shares under an at-the-market program as of May 15, raising $18.75 million in net proceeds. An at-the-market program lets a company sell new shares into the market over time, which can raise cash but may dilute existing holders.
The stock outperformed a weak biotech tape. The SPDR S&P Biotech ETF was down 3.2%, while the S&P 500 ETF was little changed. HeartBeam, another small cardiac-diagnostics name, fell 2.6%, and iRhythm Technologies, a larger cardiac-monitoring company, dropped 2.6%.
The peer read-through is limited. HeartBeam is developing technology for detecting and monitoring cardiac conditions, while iRhythm sells cardiac-monitoring services; Cardio is trying to commercialize blood-based cardiovascular risk and detection tests, a different route into the same broad heart-disease market.
But the risk case is still plain. Cardio said sales and partnership cycles can be long, in some cases up to 24 months, and broad adoption of new diagnostics can take years. The filing also said disclosure controls were not effective, remediation work was not yet fully tested, and the company expects to rely mainly on its at-the-market offering for the rest of 2026 if market conditions allow.
For now, the next markers are commercial rather than clinical: the June 4 and June 9 meetings in Philadelphia, a June 12 benefits-fund meeting in Illinois, and a June 25-26 employee-health conference in Chicago. For a company with nominal revenue, investor reaction will likely hinge on whether that exposure turns into signed customers, reimbursement progress or another update with numbers attached.
